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of RA activity such as disease activity score (DAS28) 
and CRP levels. Rituximab therapy, beside a rapid clini-
cal improvement, reduced serum MMPs concentrations in 
RA patients refractory to anti-TNF treatment. Repeated 
infusions of rituximab maintained initial serum MMPs 
suppression.
Keywords MMP-1 · MMP-3 · MMP-9 · TIMP-1 · 
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Introduction
Rheumatoid arthritis (RA) is a chronic, progressive autoim-
mune disease from which suffer about 1 % of adult popu-
lation [1]. Morphologically disease is characterized by an 
invasive and tissue destructive infiltrate of lymphocytes, 
macrophages and synoviocytes in the joint [2]. Matrix met-
alloproteinases (MMPs) produced by macrophages and syn-
ovial fibroblasts were shown to be involved in the articular 
tissues destruction [3–5]. The activity of MMPs is down-
regulated by tissue inhibitor of metalloproteinases (TIMPs), 
which neutralize MMPs. Therefore, MMPs and TIMPs and 
especially their imbalance are supposed to be engaged in the 
process of the joint tissues remodeling in RA [6–8].
Because production of MMPs is controlled among others 
by TNF-α [5], it was suggested to use anti-TNF agents in the 
treatment of RA. TNF inhibitors revealed to be very effective 
at improving signs and symptoms of disease, however, not 
in all patients [9]. Therefore, a monoclonal antibody directed 
against CD20+ B cells was developed to induce transient 
depletion of B cells which were shown to stimulate MMPs 
synthesis by macrophages and fibroblasts [5, 10, 11]. Treat-
ment with rituximab, a monoclonal antibody directed against 
CD20+ B cells, showed significant improvements in disease 
Abstract In our article, we evaluated the regulatory 
effects of the infusions of rituximab, a monoclonal anti-
body directed against CD20+ B cells, on the serum matrix 
metalloproteinases (MMPs) and tissue inhibitor of metallo-
proteinases-1 (TIMP-1) levels in patients with active rheu-
matoid arthritis (RA) not responding to anti-tumor necro-
sis factor (anti-TNF) therapy. Twelve RA patients were 
planned to receive four infusions of 1,000 mg of rituximab 
at weeks 0, 2, 24 and 26. The therapy was combined with 
methotrexate (MTX) (20–30 mg/week). Seven patients 
were refractory to previously received infliximab, and five 
to etanercept. Serum concentrations of interstitial colla-
genase (MMP-1), stromelysin-1 (MMP-3), gelatinase B 
(MMP-9) and TIMP-1 were measured by ELISA on weeks 
0, 2, 12, 24, 36 and 52. Initial infusion of rituximab down-
regulated serum MMP-1 (p < 0.01), MMP-3 (p < 0.001), 
MMP-9 (p < 0.001) and TIMP-1 (p < 0.05) levels. Sec-
ond drug administration caused even more remarkable 
reduction of measured MMPs (p < 0.001 in all cases) and 
TIMP-1 level (p < 0.01). These findings were accompanied 
by significantly decreased ratios of measured MMPs to 
TIMP-1. Next rituximab infusions on weeks 24 and 26 sus-
tained the suppression of serum MMPs levels. Prior to the 
initial rituximab infusion, serum concentrations of studied 
MMPs and TIMP-1 significantly correlated with markers 
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activity in patients with active RA who had an inadequate 
response or intolerance to TNF inhibitor [9]. It was even 
shown that rituximab can inhibit the progression of structural 
joint damage in these patients [12].
In our previous study, we demonstrated that repeated 
infusions of the chimeric anti-TNF-α monoclonal antibody 
(infliximab), beside the decrease in RA activity, reduce 
serum levels of MMP-1, MMP-3 and MMP-9 [13]. The 
aim of the present study was to evaluate the effects of the 
administration of rituximab on serum MMPs and TIMP-1 
levels and ratios of MMPs to TIMPs in patients with active 
RA not responding to anti-tumor necrosis factor therapy.
Materials and methods
Patients and samples
A total of 12 patients who fulfilled the American College 
of Rheumatology 1987 revised criteria for RA [14] were 
enrolled into an open (non-placebo-controlled) study. 
None of the patients had previous history of tuberculosis or 
symptoms of infectious diseases in the last 3 months. Chest 
X-rays performed before first rituximab infusion were nor-
mal in all patients.
Patients recruited to the study had active RA and had an 
inadequate response to 6 months anti-tumor necrosis factor 
therapies with infliximab (seven patients) and etanercept 
(five patients). Clinical and demographic characterization 
of patients is shown in Table 1. All participants were receiv-
ing methotrexate (MTX) (median 25.0 mg/week, range 
20–30 mg/week) in a stable dose for at least 3 months and 
nonsteroidal anti-inflammatory drugs (NSAIDs) in a stable 
dose for at least 4 weeks before enrollment into the study. 
Ten patients were receiving corticosteroids (median 10 mg/
day of prednisone, range 5–15 mg/day) in a stable dose for 
at least 4 weeks before beginning of the trial. Such treat-
ment regimen with MTX, NSAIDs and prednison was con-
tinued through the whole study.
Patients were supposed to have four infusions of 
1,000 mg of rituximab at weeks 0, 2, 24 and 26. Blood 
samples obtained prior infusions from on weeks 0, 2, 24 
and additionally on weeks 12, 36 and 52 were clotted for 
30 min and next centrifuged for 10 min at 1,000g. Serum 
aliquots were stored at −80 °C. The study protocol was 
approved by the local ethical committee, and patients’ writ-
ten consent was obtained.
Clinical and laboratory assessment
The evaluation included the number of tender joints (of 
28 joints assessed), the number of swollen joints (of 28 
assessed), erythrocyte sedimentation rate (ESR), patient’s 
global assessment of disease activity (VAS), disease activ-
ity score with four variables (DAS28), C-reactive protein 
(CRP) concentration measured by radial immunodiffusion 
kit (Nanorid, The Binding Site Ltd., Birmingham, UK), 
rheumatoid factor level and anti-citrullinated cyclic peptide 
(anti-CCP) antibodies measured by commercial ELISA kits 
(Euroimmun, Medizinische Labordiagnostika AG, Lübeck, 
Germany). Radiological analysis of the joint destruction 
was performed according to Steinbrocker’s criteria [15].
Enzyme-linked immunosorbent assays (ELISA)
The measurements of serum concentrations of interstitial col-
lagenase (MMP-1, matrix metalloproteinases 1), stromely-
sin-1 (MMP-3), gelatinase B (MMP-9) and tissue inhibitor of 
metalloproteinases 1 (TIMP-1) were based on a commercial 
ELISA kits (Biotrak, Amersham Pharmacia Biotech Limited, 
Little Chalfont Buckinghamshire, England) and performed 
strictly according to the manufacturer’s instructions.
Statistical analysis
The normally distributed data were compared by paired 
Student t test. Wilcoxon signed rank test was used to evalu-
ate the differences between non-normally distributed data. 
Correlations between variables were assessed by Spearman 
rank order test. p values lower than 0.05 were considered 
statistically significant.
Results
Serum levels of MMPs and TIMP-1
First rituximab administration caused significant reduc-
tion in the concentration of interstitial collagenase 
Table 1  Clinical and demographic characterization of RA patients
Data are presented as mean ± SD
RA rheumatoid arthritis, RF rheumatoid factor
a
 According to Steinbrocker’s criteria
RA patients
Sex (F/M) 8/4
Mean age (years) 56.7 ± 11.7
Mean disease duration (years) 14.5 ± 9.4
No. of RF-positive patients 10
No. of patients with anti-citrullinated cyclic peptide 
antibodies
12
Radiological stage IIa, patients 2
Radiological stage IIIa, patients 5
Radiological stage IVa, patients 5
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(MMP-1) in serum of RA patients (p < 0.01) as evalu-
ated on week 2, prior to the next drug infusion (Fig. 1, 
Figure 1S). The most decreased serum level of MMP-1 
was noticed following the second rituximab infusion 
(p < 0.001). Next two administrations of the drug sustained 
MMP-1 suppression, although were less effective as com-
pared to initial doses of rituximab. Also serum concentra-
tion of stromelysin-1 (MMP-3) diminished after rituximab 
infusion (p < 0.001) (Fig. 2, Figure 2S). MMP-3 especially 
dropped following second rituximab infusion (p < 0.001). 
Further two doses of rituximab maintained MMP-3 sup-
pression in serum of RA patients. Moreover, also serum 
concentration of gelatinase B (MMP-9) was downregulated 
in RA patients after rituximab administration (p < 0.001) 
(Fig. 3, Figure 3S). Serum MMP-9 concentration, similar 
to MMP-1 and MMP-3, decreased especially following 
second rituximab infusion (p < 0.001). Further two drug 
doses sustained MMP-9 suppression, although were less 
effective.
Serum levels of TIMP-1 also diminished following first 
two administrations of rituximab (p < 0.05 and p < 0.01 
respectively) (Fig. 4, Figure 4S). Further observation of 
serum TIMP-1 revealed even the tendency of their increase 
toward the initial values.
Suppression of serum MMPs and TIMP-1 concentra-
tions was accompanied by significantly diminished ratios 
of analyzed MMPs to TIMP-1 especially marked after 
second rituximab administration (Fig. 5). Next two doses 
of rituximab maintained MMPs/TIMP-1 ratios suppression 
in serum of RA patients.
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Fig. 1  Serum concentrations of interstitial collagenase (MMP-1, 
matrix metalloproteinase 1) in RA patients, assessed by ELISA tech-
nique. Patients were treated with rituximab (1,000 mg) on weeks 0, 
2, 24 and 26. Blood samples were obtained on weeks 0, 2, 24 prior to 
infusion of rituximab, and on weeks 12, 36 and 52. Box plots repre-
sent median (line), 25th and 75th percentiles (box), and 10th and 90th 
percentiles (whiskers). Significance of differences between pre-infu-
sion MMP-1 values on week 0 and following weeks was expressed 
as: *p < 0.05, **p < 0.01, ***p < 0.001. Significance of differences 
between pre-infusion MMP-1 values on week 2 and following weeks 
was expressed as: #p < 0.05, ##p < 0.01, ###p < 0.001
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Fig. 2  Serum concentrations of stromelysin-1 (MMP-3) in RA 
patients, assessed by ELISA technique. Patients were treated with 
rituximab (1,000 mg) on weeks 0, 2, 24 and 26. Blood samples 
were obtained on weeks 0, 2, 24 prior to infusion of rituximab, and 
on weeks 12, 36 and 52. Box plots represent median (line), 25th and 
75th percentiles (box), and 10th and 90th percentiles (whiskers). 
Significance of differences between pre-infusion MMP-1 values on 
week 0 and following weeks was expressed as: *p < 0.05, **p < 0.01, 
***p < 0.001. Significance of differences between pre-infusion 
MMP-1 values on week 2 and following weeks was expressed as: 
#p < 0.05, ##p < 0.01
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Fig. 3  Serum concentrations of gelatinase B (MMP-9) in RA 
patients, assessed by ELISA technique. Patients were treated with 
rituximab (1,000 mg) on weeks 0, 2, 24 and 26. Blood samples 
were obtained on weeks 0, 2, 24 prior to infusion of rituximab, and 
on weeks 12, 36 and 52. Box plots represent median (line), 25th and 
75th percentiles (box), and 10th and 90th percentiles (whiskers). 
Significance of differences between pre-infusion MMP-1 values on 
week 0 and following weeks was expressed as: *p < 0.05, **p < 0.01, 
***p < 0.001. Significance of differences between pre-infusion 
MMP-1 values on week 2 and following weeks was expressed as: 
#p < 0.05, ##p < 0.01
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Correlations between serum levels of MMPs or TIMP-1 
and clinical data
Suppression of serum MMPs and TIMP-1 concentrations 
were also accompanied by significantly decreased CRP lev-
els especially marked following second rituximab infusion 
(Figure 5S).
Prior to the initial rituximab administration, serum levels 
of MMP-1 correlated with marker of RA activity such as 
the 4 variables disease activity score (DAS28) (p < 0.05). 
Serum concentration of MMP-3, MMP-9 and TIMP-1 
correlated with DAS28 (p < 0.01, p < 0.001 and p < 0.05, 
respectively) and CRP (p < 0.01, p < 0.05 and p < 0.05, 
respectively)—Table 2. Such associations were also noted 
after further drug infusions, but were less or no significant. 
We did not notice any significant correlations between 
patient age, disease duration or rheumatoid factor with any 
serum MMPs or TIMP-1 concentrations.
Clinical response
Disease activity score with four variables (DAS28) signifi-
cantly diminished following initial administration of rituxi-
mab (p < 0.001). Second drug infusion leaded to even more 
remarkable drop of DAS28 (p < 0.001). Next two doses 
of the drug caused further decrease of this score (Fig. 6). 
Reduction of the DAS28 was accompanied by decrease of 
CRP levels (p < 0.001) (data not shown).
Discussion
Several studies revealed that MMPs and TIMPs, and espe-
cially the disturbances of the enzyme to inhibitor ratios, are 
involved in the degradation of the articular components in 
the course of RA [3, 6, 8]. Because MMPs production was 
proven to be under control of such cytokines such as tumor 
necrosis factor alpha (TNF-α), [5] anti-TNF drugs were 
suggested for RA therapy. Single [7] and repeated [13] 
infusions of the chimeric anti-tumor necrosis factor alpha 
(anti-TNF-α) monoclonal antibody, infliximab, beside the 
decrease in RA activity, diminished serum levels of MMP-
1, MMP-3 and MMP-9. Because further studies revealed 
that some RA patients may be not responding or intoler-
ant to anti-TNF therapy a monoclonal antibody against 
CD20+ B cells were used to cause transient depletion of B 
cells which are known to stimulate MMPs production by 
synovial cells [5, 10, 11]. Therefore, the aim of our present 
study was to evaluate the effects of the repeated infusions 
of rituximab, a monoclonal antibody against CD20+ B 
cells, on the serum MMP-1, MMP-3, MMP-9 and TIMP-1 
levels, and ratios of measured MMPs to TIMP-1 in patients 
with active RA refractory to anti-TNF treatment.
MMP-1 called also as interstitial collagenase, produced 
mainly by synovial fibroblasts and engaged in the destruc-
tion of cartilage and synovium [5, 16, 17], was showed to 
be present in the serum of RA patients [18]. Furthermore, 
increased MMP-1 levels in early RA [16] correlate with the 
number of erosions [3], demonstrating its important role 
in process of joint destruction even in early stages of the 
disease. In our study, initial rituximab infusion significantly 
diminished the concentration of MMP-1 in serum of RA 
patients, which especially dropped after second rituximab 
infusion. Further two administrations of the drug sustained 
MMP-1 suppression, although were less effective as com-
pared to initial two doses of rituximab. Subgroup of seven 
patients pretreated with infliximab shown a stronger reduc-
tion of serum levels of MMP-1 following rituximab infu-
sions, compared to the five patients previously treated with 
etanercept.
Also MMP-3 known as stromelysin-1, whose the main 
source are fibroblasts, plays an important role in enzyme 
degradation of several components of extracellular matrix 
and different types of collagens [17]. Abundance of MMP-3 
was observed not only in the serum of long-standing RA 
patients [18, 19] but also in early stages of the disease [16]. 
Therefore, MMP-3 was suggested as a useful marker of dis-
ease activity in RA [16, 18]. Furthermore, similar MMP-1 
also elevated MMP-3 concentrations even in early RA cor-
relate with the number of erosions and disease progression 
[3, 20]. Thus, it was proposed that MMP-3 may be used in 
prediction of joint destruction in early RA. We showed that 
also serum concentration of MMP-3 was downregulated 
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Fig. 4  Serum concentrations of tissue inhibitor of metalloprotein-
ases-1 (TIMP-1) in RA patients, assessed by ELISA technique. 
Patients were treated with rituximab (1,000 mg) on weeks 0, 2, 24 
and 26. Blood samples were obtained on weeks 0, 2, 24 prior to infu-
sion of rituximab, and on weeks 12, 36 and 52. Box plots represent 
median (line), 25th and 75th percentiles (box), and 10th and 90th per-
centiles (whiskers). Significance of differences between pre-infusion 
MMP-1 values on week 0 and following weeks was expressed as: 
*p < 0.05, **p < 0.01
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after rituximab administration, especially following sec-
ond infusion of this drug. MMP-3 suppression in serum 
of RA patients was maintained by next two doses of this 
study drug. Decrease of plasma levels of MMP-3 was also 
shown in a case report of diffuse large B-cell lymphoma, 
not otherwise specified (DLBCL, NOS) associated with 
RA treated with six courses of rituximab plus cyclophos-
phamide, doxorubicin, vincristine and prednisone therapy 
[21]. However in such complex immunosuppressive ther-
apy courses repeated six times, it is difficult to point which 
immunosuppressive agent was the most important in dem-
onstrated MMP-3 suppression. Furthermore, diminished 
A
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Fig. 5  Serum concentration ratios of MMPs to tissue inhibitor of metal-
loproteinases 1 (TIMP-1). MMP-1:TIMP-1 ratios (a). MMP-3:TIMP-1 
ratios (b). MMP-9:TIMP-1 ratios (c). Serum concentrations of metal-
loproteinases and TIMP-1 in RA patients were assessed by ELISA 
technique. Patients were treated with rituximab (1,000 mg) on weeks 
0, 2, 24 and 26. Blood samples were obtained on weeks 0, 2, 24 prior 
to infusion of rituximab, and on weeks 12, 36 and 52. Significance of 
differences between pre-infusion serum concentration ratios of MMPs 
to TIMP-1 values on week 0 and following weeks was expressed 
as: *p < 0.05, **p < 0.01, ***p < 0.001. Significance of differences 
between pre-infusion serum concentration ratios of MMPs to TIMP-1 
values on week 2 and following weeks was expressed as: #p < 0.05
Table 2  Correlations between serum concentrations of studied 
MMPs or tissue inhibitor of metalloproteinases-1 (TIMP-1) and 
C-reactive protein (CRP) or disease activity score (DAS28) in RA 
patients before rituximab therapy
Data expressed as r values (correlation coefficient) according to 
Spearman rank correlation
* p < 0.05; ** p < 0.01; *** p < 0.001
CRP MMP-1 MMP-3 MMP-9 TIMP-1
DAS28 0.827*** 0.643* 0.741** 0.811*** 0.643*
CRP 0.508 0.753** 0.701* 0.651*
Weeks





















Fig. 6  Disease activity score with four variables (DAS28). Patients 
were treated with rituximab (1,000 mg) on weeks 0, 2, 24 and 26. 
Blood samples for erythrocyte sedimentation rate (ESR) assessments 
were obtained on weeks 0, 2, 24 prior to infusion of rituximab, and 
on weeks 12, 36 and 52. Box plots represent median (line), 25th and 
75th percentiles (box), and 10th and 90th percentiles (whiskers). Sig-
nificance of differences between pre-infusion DAS28 values on week 
0 and following weeks was expressed as: ***p < 0.001. Significance 
of differences between pre-infusion DAS28 values on week 2 and fol-
lowing weeks was expressed as: ###p < 0.001. Also the differences 
between pre-infusion DAS28 values on week 12 and following weeks 
24, 36 and 52 were significant (p < 0.05, p < 0.01 and p < 0.001, 
respectively) (data not shown). Furthermore difference between 
pre-infusion DAS28 value on week 24 and week 52 was significant 
(p < 0.01) (data not shown)
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serum MMP-3 was also presented in patients with antineu-
trophil cytoplasmic antibody (ANCA)-associated vasculitis 
(AAV) treated with rituximab [22].
Gelatinase B (MMP-9), produced mainly by granulo-
cytes, was found in high amounts in sera of RA patients 
even in early stages of the disease [16]. MMP-9 was shown 
to be engaged in degradation of not only gelatins but also 
elastin, aggrecans and link protein [23]. In our study, also 
serum levels of gelatinase B (MMP-9) decreased in RA 
patients after rituximab administration. Serum MMP-9 
concentration, similar to MMP-1 and MMP-3, dimin-
ished especially after second rituximab infusion. Similar 
to MMP-1 and MMP-3, further two drug doses sustained 
MMP-9 suppression, although were less effective. It was 
demonstrated by others that rituximab may decrease serum 
MMP-9 levels in antineutrophil cytoplasmic antibody 
(ANCA)-associated vasculitis (AAV) treated with rituxi-
mab [24]. Similar to MMP-1, subgroup of 7 patients pre-
viously treated with Infliximab had a stronger decrease of 
serum concentrations of MMP-9 after rituximab infusions, 
compared to the 5 patients treated with etanercept.
The activity of MMPs is downregulated by TIMPs, their 
endogenous inhibitors [5]. Furthermore, TIMP-1 was also 
shown to be a useful marker of fibrosis [25]. Enhanced lev-
els of TIMP-1 were found in RA serum [18] even in early 
disease [16]. In our study, we revealed that serum TIMP-1 
concentration decreases following rituximab administra-
tion. However, next drug infusions were followed by the 
tendency to the increase of serum TIMP-1 levels toward the 
initial values. Suppressed serum TIMP-1 was also shown in 
patients with antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitis (AAV) treated with rituximab [22].
It was already shown by others that the joint destruc-
tion in the pathogenesis of RA may be the result of distur-
bances between MMPs and TIMPs levels [6, 8]. Recently, 
we also demonstrated that relative production of TIMPs as 
compared to MMPs is decreased in RA, and especially in 
patients with more severe activity of the disease [18] and in 
early stages of the disease [16]. In the present study, down-
regulation of serum MMPs and TIMP-1 levels was accom-
panied by diminished ratios of measured MMPs to TIMP-
1, especially after second rituximab administration.
Observed in our study, only partial suppression of 
MMPs production caused by rituximab infusions suggests 
that probably higher doses of this drug and/or more often 
administrations of these anti-CD20 antibodies are needed 
in treatment of RA patients refractory to anti-tumor necro-
sis factor blockers. Other possibility is to use rituximab in 
combination with other biologic disease-modifying anti-
rheumatic drugs [26]. Because we are aware of the limita-
tion of our study, further research is needed to improve the 
mode and timing of anti-CD20 antibody therapy in RA.
Previously, we revealed the correlations between MMP-
1, MMP-3 and MMP-9 with some markers of disease activ-
ity in RA patients [18]. Also in the present study, before 
the first rituximab administration serum levels of studied 
MMPs and TIMP-1 correlated with markers of RA activ-
ity such as the disease activity score (DAS) or CRP levels. 
However, after further drug infusions, such associations 
were less or not significant. Similarly, in case of patients 
with diffuse large B-cell lymphoma treated with modern 
chemotherapy with or without CD20 antibody, MMP-9 and 
TIMP-1 seem to have lost their prognostic value [27].
We are aware that the small number of our patients is 
a limitation of our study. Furthermore, the correlation 
between MMPs and rituximab is still fragmentarily known.
In conclusion, monoclonal anti-CD20+ B cells antibody 
therapy (rituximab) combined with MTX, beside a sig-
nificant clinical improvement, diminished serum MMP-1, 
MMP-3, MMP-9 and TIMP-1 levels in active RA patients 
refractory to anti-TNF therapy. These observations were 
accompanied by the reduced ratios of the measured MMPs 
to TIMP-1. Further administrations of rituximab sustained 
MMPs decrease, however, to a lesser extend compared to 
the first two doses of this drug.
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